China National Accord Medicines Corporation Ltd. (SHE:000028)
China · Delayed Price · Currency is CNY 19.47
-0.37 (-1.86%)
Aug 21, 2026, 3:04 PM CST
SHE:000028 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,196 | 12,773 | 15,153 | 14,937 | 13,164 | 14,706 | |
Market Cap Growth | -17.14% | -15.71% | 1.44% | 13.47% | -10.48% | -18.89% |
Enterprise Value | 13,128 | 15,631 | 20,171 | 20,008 | 15,577 | 18,367 |
Last Close Price | 19.47 | 21.73 | 25.50 | 24.75 | 21.30 | 23.47 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.10 | 11.24 | 23.59 | 9.34 | 8.85 | 11.00 |
Forward PE | 10.30 | 10.36 | 16.43 | 10.10 | 10.14 | 10.13 |
PS Ratio | 0.15 | 0.17 | 0.20 | 0.20 | 0.18 | 0.22 |
PB Ratio | 0.51 | 0.59 | 0.73 | 0.71 | 0.68 | 0.82 |
P/TBV Ratio | 0.66 | 0.77 | 0.99 | 1.06 | 1.03 | 1.28 |
P/FCF Ratio | 32.88 | 8.99 | 5.07 | 5.71 | 5.88 | 11.45 |
P/OCF Ratio | 21.51 | 7.80 | 4.63 | 5.09 | 5.14 | 8.89 |
PEG Ratio | - | 0.27 | 3.29 | 0.70 | 0.99 | 1.13 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.18 | 0.21 | 0.27 | 0.27 | 0.21 | 0.27 |
EV/EBITDA Ratio | 5.65 | 8.09 | 6.50 | 5.22 | 6.13 | 8.21 |
EV/EBIT Ratio | 7.67 | 9.09 | 12.96 | 8.30 | 6.78 | 9.04 |
EV/FCF Ratio | 38.55 | 11.00 | 6.75 | 7.65 | 6.96 | 14.30 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.19 | 0.21 | 0.28 | 0.26 | 0.23 | 0.27 |
Debt / EBITDA Ratio | 1.76 | 1.53 | 1.85 | 1.40 | 1.22 | 1.46 |
Debt / FCF Ratio | - | 3.17 | 1.92 | 2.06 | 1.96 | 3.73 |
Net Debt / Equity Ratio | -0.05 | -0.15 | -0.08 | -0.05 | -0.08 | -0.02 |
Net Debt / EBITDA Ratio | -0.56 | -1.70 | -0.54 | -0.29 | -0.64 | -0.15 |
Net Debt / FCF Ratio | - | -2.32 | -0.56 | -0.43 | -0.73 | -0.26 |
Asset Turnover | - | 1.52 | 1.56 | 1.67 | 1.72 | 1.66 |
Inventory Turnover | - | 8.45 | 8.60 | 8.40 | 8.35 | 8.68 |
Quick Ratio | - | 1.18 | 1.16 | 1.11 | 1.06 | 1.02 |
Current Ratio | - | 1.54 | 1.52 | 1.49 | 1.51 | 1.42 |
Return on Equity (ROE) | 4.74% | 5.33% | 1.14% | 9.69% | 9.46% | 8.75% |
Return on Assets (ROA) | - | 2.23% | 2.04% | 3.34% | 3.36% | 3.08% |
Return on Invested Capital (ROIC) | 5.92% | 6.88% | 3.29% | 10.14% | 9.92% | 9.65% |
Return on Capital Employed (ROCE) | - | 7.50% | 6.80% | 10.40% | 10.60% | 10.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.61% | 8.89% | 4.24% | 10.71% | 11.29% | 9.09% |
FCF Yield | 3.04% | 11.13% | 19.72% | 17.51% | 17.00% | 8.74% |
Dividend Yield | 2.81% | 2.58% | 1.31% | 2.50% | 2.63% | 1.79% |
Payout Ratio | - | 34.01% | 93.97% | 34.96% | 38.62% | 45.68% |
Buyback Yield / Dilution | 0.23% | 0.38% | -0.26% | -0.12% | 0.00% | - |
Total Shareholder Return | 3.04% | 2.95% | 1.05% | 2.38% | 2.63% | 1.79% |